Type 2 Diabetes

Type 2 diabetes, formerly called adult-onset or noninsulindependent diabetes, is the most common form of diabetes. People can develop type 2 diabetes at any age, even during childhood. This form of diabetes usually begins with insulin resistance, a condition in which fat, muscle, and liver cells do not use insulin properly. At first, the pancreas keeps up with the added demand by producing more insulin. In time, however, it loses the ability to secrete enough insulin in response to meals. People who are overweight and inactive are more likely to develop type 2 diabetes. Treatment includes taking diabetes medicines, making wise food choices, exercising regularly, controlling blood pressure and cholesterol, and taking aspirin daily—for some.

What is Type 2 Diabetes?

Type 2 diabetes is a common metabolic condition that develops when the body fails to produce enough insulin or when insulin fails to work properly, which is referred to as insulin resistance. Insulin is the hormone that stimulates cells to uptake glucose from the blood to use for energy.

Diabetes Mellitus Type 2 Pathophysiology

Type 2 Diabetes Symptoms

Type 2 Diabetes Diagnosis

Type 2 Diabetes Screening and Prevention

Type 2 Diabetes Treatment

Living With Type 2 Diabetes

Vitamin D and Type 2 Diabetes

Is a Plant-Based Diet Good for Type 2 Diabetes?

Are Low Carbohydrate Diets Good for Type 2 Diabetes?

What is Insulin Resistance?

Insulin Resistance Pathophysiology

See more featured articles »

Causes of Insulin Resistance

Insulin Resistance Treatment

Insulin Resistance Diagnosis

Insulin Resistance Symptoms

Insulin Resistance and Parkinson's Disease

Does the Keto Diet Increase the Risk of Diabetes?

The Risks of Prediabetes

What is Diabetes?

Fibromyalgia and Diabetes

Diabetes in Men versus Women

Insulin Medication

Latest Type 2 Diabetes News and Research

Dapagliflozin plus calorie restriction boosts remission rates in adults with type 2 diabetes and obesity

Findings indicate that dapagliflozin and calorie restriction together improve weight loss and metabolic health, increasing the likelihood of diabetes remission.

24 Jan 2025

Study links circulating short-chain fatty acids to type 2 diabetes risk

Short-chain fatty acids (SCFAs) serve as key signaling molecules linking gut microbiota and host health. Microbially produced SCFAs in the colon are generally acknowledged for their beneficial effects on cardiometabolic health, including enhancing insulin secretion, reducing plasma cholesterol and glucose levels, and controlling energy intake through the modulation of enteroendocrine hormones.

24 Jan 2025

Healthy habits take longer to form than expected

We're nearly one month into 2025, but if you're struggling to hold onto your New Year's resolution, stay strong, as University of South Australia research shows that forming a healthy habit can take longer than you expect.

24 Jan 2025

Study finds successful treatment of childhood obesity lowers long-term health risks

Effective treatment of childhood obesity significantly lowers long-term health risks, including type 2 diabetes and hypertension, promoting better adult health.

24 Jan 2025

Study shows how physical activity can enhance brain function and prevent dementia

A study led by scientists at Rutgers University-New Brunswick has shown that specialized cells involved in how the body responds to insulin are activated in the brain after exercise, suggesting that physical activity may directly improve brain function.

23 Jan 2025

What causes behavioral side effects in popular weight loss drugs?

The study of GLP1R variants shows associations with cardiometabolic traits and behavioral changes, highlighting indirect effects of GLP1RA on mental health.

23 Jan 2025

Dapagliflozin and calorie restriction show higher remission rates in type 2 diabetes

Adults with overweight or obesity and type 2 diabetes who are given the sodium glucose cotransporter 2 (SGLT-2) inhibitor drug dapagliflozin alongside moderate calorie restriction achieve much higher rates of remission compared with calorie restriction alone, finds a trial published by The BMJ today.

23 Jan 2025

Why do people with obesity, but without diabetes, start taking semaglutide?

Research identifies key factors affecting semaglutide initiation among obese individuals without diabetes, revealing significant insurance coverage disparities.

22 Jan 2025

GLP1RA medications linked to behavioral side effects in type 2 diabetes and obesity

Glucagon-like peptide 1 receptor agonists (GLP1RA)-medications for type 2 diabetes and obesity that have recently been making headlines due to a rise in popularity as weight loss agents-have been linked with behavioral side effects.

22 Jan 2025

Global research uncovers varying diabetes mortality risks by ethnicity

While advances in diabetes care have improved survival rates, this study highlights persistent ethnic disparities in mortality risk, urging tailored healthcare strategies to address diverse needs.

22 Jan 2025

How gut microbiota impacts childhood obesity

Gut microbiota plays a critical role in childhood obesity by influencing energy metabolism, inflammation, and appetite regulation, with emerging therapeutic strategies like probiotics, dietary interventions, and fecal microbiota transplantation showing promise.

21 Jan 2025

Childhood obesity treatment reduces long-term health risks but not depression

When children with obesity undergo weight-loss treatment, the effects have repercussions later in life and the risk of serious health problems and premature death is lower as they reach young adulthood.

21 Jan 2025

How lifestyle-based interventions help manage PCOS

Studies indicate that lifestyle modifications can alleviate PCOS symptoms, improving insulin resistance and hormonal balance through diet and physical activity.

21 Jan 2025

Researchers create an atlas of health associations for GLP-1 receptor agonists

Insights from a study on GLP-1 receptor agonists reveal benefits for cardiometabolic health, with notable risks for gastrointestinal and musculoskeletal issues.

20 Jan 2025

Manuka vs. Ohia Lehua honey: Study reveals key antioxidant differences and health benefits

Study compares the antioxidant properties of Manuka honey (MH) and Ohia Lehua honey (OLH), revealing that MH contains ten times more phenolic content, while OLH demonstrates superior in vivo antioxidant activity by reducing oxidative stress and enhancing antioxidant capacity.

19 Jan 2025